MX2010010485A - Compuesto calcimimetico para su uso en el tratamiento de lesiones epiteliales. - Google Patents

Compuesto calcimimetico para su uso en el tratamiento de lesiones epiteliales.

Info

Publication number
MX2010010485A
MX2010010485A MX2010010485A MX2010010485A MX2010010485A MX 2010010485 A MX2010010485 A MX 2010010485A MX 2010010485 A MX2010010485 A MX 2010010485A MX 2010010485 A MX2010010485 A MX 2010010485A MX 2010010485 A MX2010010485 A MX 2010010485A
Authority
MX
Mexico
Prior art keywords
treatment
epithelial injury
calcimimetic compound
injury
calcimimetic
Prior art date
Application number
MX2010010485A
Other languages
English (en)
Inventor
Ng Gordon
Martin David
Peter Geibel John
Charles Hebert Steven (Fallecido) Representado Por Su Heredera Sra Patricia R Hebert
G Richard William
L Viney Joanne
Original Assignee
Amgen Inc Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc Star filed Critical Amgen Inc Star
Publication of MX2010010485A publication Critical patent/MX2010010485A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere en general al campo de la medicina y, más específicamente, a métodos para el tratamiento de una lesión epitelial, en particular, debido a isquemia, hipoxia, trauma, substancias quimiolíticas o exposición a radiación.
MX2010010485A 2008-03-28 2009-03-27 Compuesto calcimimetico para su uso en el tratamiento de lesiones epiteliales. MX2010010485A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7226408P 2008-03-28 2008-03-28
PCT/US2009/038659 WO2009121015A2 (en) 2008-03-28 2009-03-27 Methods of treating epithelial injury

Publications (1)

Publication Number Publication Date
MX2010010485A true MX2010010485A (es) 2011-03-30

Family

ID=40800243

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010010485A MX2010010485A (es) 2008-03-28 2009-03-27 Compuesto calcimimetico para su uso en el tratamiento de lesiones epiteliales.

Country Status (7)

Country Link
US (1) US8609655B2 (es)
EP (1) EP2278961A2 (es)
JP (1) JP2011516424A (es)
AU (1) AU2009228069B9 (es)
CA (1) CA2719256A1 (es)
MX (1) MX2010010485A (es)
WO (1) WO2009121015A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9902703B2 (en) 2015-07-01 2018-02-27 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1275635A1 (en) 1994-10-21 2003-01-15 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
US6908935B2 (en) 2002-05-23 2005-06-21 Amgen Inc. Calcium receptor modulating agents
US8486381B2 (en) * 2005-09-02 2013-07-16 Amgen Inc. Methods of modulating intestinal fluid balance
KR20080110681A (ko) * 2006-04-20 2008-12-18 암겐 인코포레이티드 안정적 에멀젼 조제물
JP5470653B2 (ja) * 2006-10-26 2014-04-16 アムジエン・インコーポレーテツド カルシウム受容体調節剤
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
CA2681582C (en) 2007-03-30 2015-07-14 Amgen Inc. Methods of treating bowel disorders

Also Published As

Publication number Publication date
AU2009228069A1 (en) 2009-10-01
CA2719256A1 (en) 2009-10-01
EP2278961A2 (en) 2011-02-02
US8609655B2 (en) 2013-12-17
WO2009121015A2 (en) 2009-10-01
WO2009121015A3 (en) 2009-11-26
JP2011516424A (ja) 2011-05-26
US20110144102A1 (en) 2011-06-16
AU2009228069B2 (en) 2014-05-29
AU2009228069B9 (en) 2014-07-10

Similar Documents

Publication Publication Date Title
PH12016502092A1 (en) Antimicrobial compounds and methods of making and using the same
MX2014011134A (es) Compuestos de carbamato y preparacion y uso de los mismos.
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX349827B (es) Compuestos que contienen nitrogeno y su uso.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
PH12014501738A1 (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
MX2013012253A (es) Conjugados novedosos de aglutinante-farmaco (adc) y su uso.
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
MY176900A (en) Antimicrobial compounds and methods of making and using the same
MY173518A (en) Antimicrobial compounds and methods of making and using the same
NZ708928A (en) Mannose derivatives for treating bacterial infections
MY162146A (en) Pharmaceutical composition
NZ706354A (en) 1,2,4-triazine derivatives for the treatment of viral infections.
MX340190B (es) Compuestos para tratar infecciones por virus sincitial respiratorio.
NZ700612A (en) Methods and compositions for treating ewings sarcoma family of tumors
IL211120A (en) Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
PH12015501088A1 (en) Dimeric compounds
PH12015502375B1 (en) Antimicrobial compounds and methods of making and using the same
MX2014000567A (es) Tratamiento de lesion por radiacion utilizando celulas adherentes derivadas del amnios.
MY161870A (en) Antimicrobial compounds and methods of making and using the same
WO2013166282A3 (en) Methods and compositions for treating bacterial infection
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN

Legal Events

Date Code Title Description
FG Grant or registration